Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma
ABSTRACT Backgroud Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over‐expression. Case We report the case o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.70065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577761051410432 |
|---|---|
| author | Martina Napolitano Lucia Trudu Enrica Martinelli Chiara Santini Massimo Dominici Federica Bertolini |
| author_facet | Martina Napolitano Lucia Trudu Enrica Martinelli Chiara Santini Massimo Dominici Federica Bertolini |
| author_sort | Martina Napolitano |
| collection | DOAJ |
| description | ABSTRACT Backgroud Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over‐expression. Case We report the case of a 64‐year‐old female with extra‐ and intracranial metastases of SDC with evidence of AR and HER2 overexpression. After progression on first line chemotherapy, was administered neratinib, a pan‐Erb2 receptor tyrosine kinase inhibitor. Even with central nervous system involvement at diagnosis, a durable clinical response was obtained with a PFS of 11 months and no significant toxicities to manage. Best response observed during tratment was partial response. Conclusions This case confirms the potential efficacy of neratinib in HER2‐positive SDC and underlines the need to define the best therapeutic sequence and potential biomarkers for these rare patients. |
| format | Article |
| id | doaj-art-aa47aebe2fcb48acbd56af12d654fe5a |
| institution | Kabale University |
| issn | 2573-8348 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj-art-aa47aebe2fcb48acbd56af12d654fe5a2025-01-30T15:46:35ZengWileyCancer Reports2573-83482025-01-0181n/an/a10.1002/cnr2.70065Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct CarcinomaMartina Napolitano0Lucia Trudu1Enrica Martinelli2Chiara Santini3Massimo Dominici4Federica Bertolini5Department of Oncology and Hematology Azienda Ospedaliero‐Universitaria di Modena Modena ItalyDepartment of Oncology and Hematology Azienda Ospedaliero‐Universitaria di Modena Modena ItalyDepartment of Oncology and Hematology Azienda Ospedaliero‐Universitaria di Modena Modena ItalyAULSS7 Pedemontana—Unità Operativa Complessa di Oncologia ItalyDepartment of Oncology and Hematology Azienda Ospedaliero‐Universitaria di Modena Modena ItalyDepartment of Oncology and Hematology Azienda Ospedaliero‐Universitaria di Modena Modena ItalyABSTRACT Backgroud Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over‐expression. Case We report the case of a 64‐year‐old female with extra‐ and intracranial metastases of SDC with evidence of AR and HER2 overexpression. After progression on first line chemotherapy, was administered neratinib, a pan‐Erb2 receptor tyrosine kinase inhibitor. Even with central nervous system involvement at diagnosis, a durable clinical response was obtained with a PFS of 11 months and no significant toxicities to manage. Best response observed during tratment was partial response. Conclusions This case confirms the potential efficacy of neratinib in HER2‐positive SDC and underlines the need to define the best therapeutic sequence and potential biomarkers for these rare patients.https://doi.org/10.1002/cnr2.70065head and neckHER2 targeted therapyneratinibprecision medicinesalivary duct carcinoma |
| spellingShingle | Martina Napolitano Lucia Trudu Enrica Martinelli Chiara Santini Massimo Dominici Federica Bertolini Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma Cancer Reports head and neck HER2 targeted therapy neratinib precision medicine salivary duct carcinoma |
| title | Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma |
| title_full | Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma |
| title_fullStr | Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma |
| title_full_unstemmed | Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma |
| title_short | Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma |
| title_sort | neratinib and the role of anti her2 therapy in salivary duct carcinoma |
| topic | head and neck HER2 targeted therapy neratinib precision medicine salivary duct carcinoma |
| url | https://doi.org/10.1002/cnr2.70065 |
| work_keys_str_mv | AT martinanapolitano neratinibandtheroleofantiher2therapyinsalivaryductcarcinoma AT luciatrudu neratinibandtheroleofantiher2therapyinsalivaryductcarcinoma AT enricamartinelli neratinibandtheroleofantiher2therapyinsalivaryductcarcinoma AT chiarasantini neratinibandtheroleofantiher2therapyinsalivaryductcarcinoma AT massimodominici neratinibandtheroleofantiher2therapyinsalivaryductcarcinoma AT federicabertolini neratinibandtheroleofantiher2therapyinsalivaryductcarcinoma |